When is crossover desirable in cancer drug trials and when is it problematic?

A. Haslam, V. Prasad

Research output: Contribution to journal › Editorial

3 Scopus citations

Original language	English
Number of pages	1
Journal	Annals of Oncology
Volume	29
Issue number	5
DOIs	https://doi.org/10.1093/annonc/mdy116
State	Published - 1 May 2018
Externally published	Yes

Access to Document

10.1093/annonc/mdy116

Link to publication in Scopus

Cite this

Haslam, A., & Prasad, V. (2018). When is crossover desirable in cancer drug trials and when is it problematic? Annals of Oncology, 29(5). https://doi.org/10.1093/annonc/mdy116

@article{f488465f996c48939658f0b346de93fb,

title = "When is crossover desirable in cancer drug trials and when is it problematic?",

author = "A. Haslam and V. Prasad",

year = "2018",

month = may,

day = "1",

doi = "10.1093/annonc/mdy116",

language = "English",

volume = "29",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - When is crossover desirable in cancer drug trials and when is it problematic?

AU - Haslam, A.

AU - Prasad, V.

PY - 2018/5/1

Y1 - 2018/5/1

UR - http://www.scopus.com/inward/record.url?scp=85047609411&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy116

DO - 10.1093/annonc/mdy116

M3 - Editorial

C2 - 29648572

AN - SCOPUS:85047609411

VL - 29

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

SN - 0923-7534

IS - 5

ER -